New 'Double Punch' CAR T-Cell therapy takes on tough blood cancers
NCT ID NCT06703892
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new cell therapy called GF-CART01 for people with certain B-cell blood cancers (like lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two cancer markers (CD20 and CD19) at once. The main goals are to find a safe dose and check for early signs that the treatment is working. Only 18 adults aged 18 to 70 will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GF-CART01 (a type of CAR T-cell therapy that targets two proteins, CD20 and CD19, on cancer cells)
- What this could lead to
- If it works, this could offer a new treatment option for people with hard-to-treat B-cell blood cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early (Phase 1) and small trial (18 people), so it is mainly checking safety and dosing. The treatment may not work, and there are risks of serious side effects like cytokine release syndrome or nervous system problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart returning lymphoma?
- Can a Three-Drug cocktail replace chemo for follicular lymphoma?
- Engineered immune cells take on tough lymphomas
- New drug combo aims to outsmart recurring lymphoma
- New hope for HIV patients with aggressive lymphoma: early trial launches
- Can a Macrophage-Targeting drug supercharge CAR-T therapy?